A5048214658- Asthma and respiratory diseases
- Cancer Immunotherapy and Biomarkers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Allergic Rhinitis and Sensitization
- Pulmonary Hypertension Research and Treatments
- Respiratory and Cough-Related Research
- Urticaria and Related Conditions
- Inhalation and Respiratory Drug Delivery
- Reproductive System and Pregnancy
- Occupational and environmental lung diseases
- Glaucoma and retinal disorders
- Pregnancy and Medication Impact
- Systemic Sclerosis and Related Diseases
- Vascular Tumors and Angiosarcomas
- Sarcoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Cytokine Signaling Pathways and Interactions
- Chemokine receptors and signaling
- Cerebral Venous Sinus Thrombosis
- Eosinophilic Esophagitis
Université Paris Cité
2023-2024
Physiopathologie et Epidémiologie des Maladies Respiratoires
2024
Pitié-Salpêtrière Hospital
2024
Sorbonne Université
2024
Assistance Publique – Hôpitaux de Paris
2021-2024
Hôpital Bichat-Claude-Bernard
2023-2024
Université Claude Bernard Lyon 1
2024
Institut Pierre Louis d‘Épidémiologie et de Santé Publique
2024
Sorbonne Paris Cité
2024
Inserm
2024
Introduction The gender-age-physiology (GAP) index is an easy-to-use baseline mortality prediction model in idiopathic pulmonary fibrosis (IPF). GAP does not incorporate exercise capacity parameters such as 6 min walk distance (6MWD) or exertional hypoxia. We evaluated if the addition of 6MWD and hypoxia to improves survival IPF. Methods Patients with IPF were identified at a tertiary care referral centre. Discrimination calibration original assessed. cohort was then randomly divided into...
Compared with docetaxel, the phase-III trial, ULTIMATE, showed a significant improvement of progression-free survival (PFS) paclitaxel-bevacizumab combination (PB) as second- or third-line treatment in advanced non-small cell lung cancer (NSCLC). With increase immunotherapy first-line settings, optimal after first-line failure must be redefined.This multicentric retrospective study identified all NSCLC patients treated PB second-line therapy and beyond. The main efficacy outcomes assessed were...
https://bit.ly/3vfPn4k.
Switching biologics is now common practice in severe eosinophilic asthma. After insufficient response to anti-interleukin 5 or receptor (anti-IL-5/5R), the optimal switch between an anti-IL-4R monoclonal antibody (mAb) (inter-class) another anti-IL-5/5R drug (intra-class) remains unknown. We compared effectiveness of these two strategies on asthma control patients with and mAb. emulated a target randomized trial using observational data from RAMSES Cohort. Eligible were switched mAb after...
e21086 Background: With the growing role of immunotherapy (ICI) as first-line setting for advanced NSCLC, strategies must be redefined after failure. The combination paclitaxel-bevacizumab showed in ULTIMATE trial a significant superiority versus docetaxel second or third-line treatment. Limited restropective studies has demonstrated unexpected efficacy chemotherapy prior progression on ICI. This could use salvage treatment following Methods: multi-centric retrospective study identifies...
Rationale: The Gender, Age, and Physiology (GAP) index has proven to be an easy tool for predicting disease stage survival in idiopathic pulmonary fibrosis (IPF) patients.However, how this scoring system performs the era of antifibrotic therapies not been fully evaluated.Our objective was validate mortality risk or need lung transplantation as determined by GAP score a real-life IPF population on therapy.Methods: We included all patients with evaluated at our facility who received either...
Rationale: The impact of antifibrotic treatments on the prognosis patients with idiopathic pulmonary fibrosis (IPF) is still debated.We sought to evaluate IPF and their response treatment in a large single-center study.Methods: We included all evaluated at our facility from 2009 2019.Demographic, physiologic, functional, outcome data were collated.Patients distributed according Gender, Age, Physiology (GAP) stage use or not one other validated therapy.Primary was all-cause mortality lung...